EUCTR2019-004511-31-IT进行中（未招募）1 期
Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA0 个研究点目标入组 135 人开始时间: 2020年10月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for the screening phase:
- •1. Diagnosed with cystic fibrosis (genetic diagnosis and clinical phenotype of lung disease)
- •2. Age = 8 yrs and < 18 yrs
- •3. Able to produce a sputum sample (spontaneous or induced sputum)
- •4. Informed Consent given
- •Inclusion criteria for the intervention phase:
- •1. Diagnosed with cystic fibrosis (genetic diagnosis and/or abnormal sweat test and clinical phenotype of lung disease)
- •2. Age = 8 yrs and < 18 yrs
- •3. Presence of Aspergillus infection as defined for this study
- •4. Clinically stable condition without a significant change in lung function (FEV1 +/- 10%) or significant worsening of respiratory symptoms over the previous month
- •5. Able to perform lung function test (FEV1)
- •6. Able to produce a sputum sample (spontaneous or induced sputum)
- •7. Informed Consent given
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria for the trial:
- •1. Age < 8 yrs or = 18 yrs
- •2. Unable to perform lung function test (FEV1)
- •3. Unable to produce a sputum sample (spontaneous or induced sputum)
- •4. Clinically unstable condition with significant change in lung function or significant worsening of respiratory symptoms
- •5. Unable to tolerate oral medication
- •6. Known hypersensitivity to the drug/excipients
- •7. On active transplant list or transplant recipient
- •8. Azole resistant Aspergillus sp. cultured
- •9. Patients receiving terfenadine, ergot alkaloids, astemizole, cisapride, pimozide, halofantrine, quinidine, or HMG-CoA reductase inhibitors metabolised through CYP3A4
- •10. Patients receiving omalizumab
- •11. Received systemic mould-active antifungals in the last month
- •12. Shortened or elongated QT interval
- •13. Cardiac failure
- •14. ALT = 200 U/L
- •15. AST = 225 U/L
- •16. Alkaline phosphatase = 460 U/L
- •17. Bilirubin = 50 umol/L
- •18. Pregnancy
- •19. Informed Consent not given
研究者
相似试验
进行中（未招募）
1 期
Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.EUCTR2019-004511-31-ESBambino Gesù Children´s Hospital135
进行中（未招募）
1 期
Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.EUCTR2019-004511-31-IEBambino Gesù Children's Hospital135
进行中（未招募）
1 期
Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.Cystic Fibrosis and Aspergillus infection.MedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862EUCTR2019-004511-31-PTBambino Gesù Children's Hospital135
进行中（未招募）
1 期
Prospective validation and clinical evaluation of a new posaconazole dosingregimen for children and adolescents with cystic fibrosis and Aspergillus infection.Cystic Fibrosis and Aspergillus InfectionMedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862EUCTR2019-004511-31-GBBambino Gesù Children's Hospital135
进行中（未招募）
1 期
Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.EUCTR2019-004511-31-NLBambino Gesù Children's Hospital135